SERES THERAPEUTICS INC (MCRB) Fundamental Analysis & Valuation

NASDAQ:MCRB • US81750R2013

8.93 USD
-0.02 (-0.22%)
Last: Mar 11, 2026, 08:10 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This MCRB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, MCRB scores 2 out of 10 in our fundamental rating. MCRB was compared to 519 industry peers in the Biotechnology industry. While MCRB seems to be doing ok healthwise, there are quite some concerns on its profitability. MCRB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. MCRB Profitability Analysis

1.1 Basic Checks

  • MCRB had negative earnings in the past year.
  • MCRB had a negative operating cash flow in the past year.
  • MCRB had negative earnings in 4 of the past 5 years.
  • In the past 5 years MCRB reported 4 times negative operating cash flow.
MCRB Yearly Net Income VS EBIT VS OCF VS FCFMCRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M -250M

1.2 Ratios

  • MCRB has a Return On Assets of 3.76%. This is amongst the best in the industry. MCRB outperforms 90.17% of its industry peers.
  • With an excellent Return On Equity value of 12.34%, MCRB belongs to the best of the industry, outperforming 93.26% of the companies in the same industry.
Industry RankSector Rank
ROA 3.76%
ROE 12.34%
ROIC N/A
ROA(3y)-34.45%
ROA(5y)-29.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MCRB Yearly ROA, ROE, ROICMCRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

  • MCRB has a Profit Margin of 1536.75%. This is amongst the best in the industry. MCRB outperforms 99.42% of its industry peers.
  • The Operating Margin and Gross Margin are not available for MCRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 1536.75%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MCRB Yearly Profit, Operating, Gross MarginsMCRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MCRB Health Analysis

2.1 Basic Checks

  • MCRB has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MCRB has been increased compared to 5 years ago.
  • There is no outstanding debt for MCRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MCRB Yearly Shares OutstandingMCRB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
MCRB Yearly Total Debt VS Total AssetsMCRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • MCRB has an Altman-Z score of -10.99. This is a bad value and indicates that MCRB is not financially healthy and even has some risk of bankruptcy.
  • MCRB's Altman-Z score of -10.99 is on the low side compared to the rest of the industry. MCRB is outperformed by 74.76% of its industry peers.
  • MCRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.99
ROIC/WACCN/A
WACCN/A
MCRB Yearly LT Debt VS Equity VS FCFMCRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

2.3 Liquidity

  • A Current Ratio of 2.30 indicates that MCRB has no problem at all paying its short term obligations.
  • MCRB's Current ratio of 2.30 is on the low side compared to the rest of the industry. MCRB is outperformed by 73.22% of its industry peers.
  • A Quick Ratio of 2.30 indicates that MCRB has no problem at all paying its short term obligations.
  • The Quick ratio of MCRB (2.30) is worse than 70.52% of its industry peers.
Industry RankSector Rank
Current Ratio 2.3
Quick Ratio 2.3
MCRB Yearly Current Assets VS Current LiabilitesMCRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MCRB Growth Analysis

3.1 Past

  • MCRB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 73.57%, which is quite impressive.
EPS 1Y (TTM)73.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 21.59% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y103.73%
EPS Next 2Y24.24%
EPS Next 3Y12.91%
EPS Next 5Y21.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MCRB Yearly Revenue VS EstimatesMCRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2025 50M 100M 150M
MCRB Yearly EPS VS EstimatesMCRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. MCRB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MCRB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MCRB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MCRB Price Earnings VS Forward Price EarningsMCRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MCRB Per share dataMCRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6 -8

4.3 Compensation for Growth

  • MCRB's earnings are expected to grow with 12.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.24%
EPS Next 3Y12.91%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MCRB Dividend Analysis

5.1 Amount

  • MCRB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MCRB Fundamentals: All Metrics, Ratios and Statistics

SERES THERAPEUTICS INC

NASDAQ:MCRB (3/11/2026, 8:10:06 PM)

8.93

-0.02 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)03-11
Inst Owners23.58%
Inst Owner Change1102.52%
Ins Owners0.38%
Ins Owner Change0.7%
Market Cap80.82M
Revenue(TTM)351.00K
Net Income(TTM)5.39M
Analysts77.78
Price Target21.42 (139.87%)
Short Float %9.79%
Short Ratio10.38
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.64%
Min EPS beat(2)-28%
Max EPS beat(2)10.71%
EPS beat(4)2
Avg EPS beat(4)-101.12%
Min EPS beat(4)-437.4%
Max EPS beat(4)50.19%
EPS beat(8)5
Avg EPS beat(8)-46.98%
EPS beat(12)6
Avg EPS beat(12)-33.14%
EPS beat(16)6
Avg EPS beat(16)-27.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)1.25%
EPS NQ rev (3m)3.54%
EPS NY rev (1m)0%
EPS NY rev (3m)2.16%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 230.25
P/FCF N/A
P/OCF N/A
P/B 1.85
P/tB 1.85
EV/EBITDA N/A
EPS(TTM)-6.29
EYN/A
EPS(NY)-8.85
Fwd EYN/A
FCF(TTM)-2.58
FCFYN/A
OCF(TTM)-2.55
OCFYN/A
SpS0.04
BVpS4.83
TBVpS4.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 3.76%
ROE 12.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1536.75%
GM N/A
FCFM N/A
ROA(3y)-34.45%
ROA(5y)-29.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.34%
Cap/Sales 89.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.3
Quick Ratio 2.3
Altman-Z -10.99
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)94.28%
Cap/Depr(5y)90.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%112.37%
EPS Next Y103.73%
EPS Next 2Y24.24%
EPS Next 3Y12.91%
EPS Next 5Y21.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.86%
EBIT Next 3Y9.36%
EBIT Next 5YN/A
FCF growth 1Y82.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y81.22%
OCF growth 3YN/A
OCF growth 5YN/A

SERES THERAPEUTICS INC / MCRB FAQ

What is the ChartMill fundamental rating of SERES THERAPEUTICS INC (MCRB) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MCRB.


What is the valuation status for MCRB stock?

ChartMill assigns a valuation rating of 0 / 10 to SERES THERAPEUTICS INC (MCRB). This can be considered as Overvalued.


What is the profitability of MCRB stock?

SERES THERAPEUTICS INC (MCRB) has a profitability rating of 2 / 10.


What is the financial health of SERES THERAPEUTICS INC (MCRB) stock?

The financial health rating of SERES THERAPEUTICS INC (MCRB) is 5 / 10.